| Exon 2-3 | Exon 4 | P |
---|---|---|---|
N | 23 | 50 | Â |
Male, n (%) | 14 (60.87%) | 29 (58.00%) | 8.17 × 10-1C |
Ethnicities Caucasian/East Asian/African, n (%) | 20/3/0 (86.96/13.04/0.00) | 44/5/1 (88.00/10.00/2.00) | 7.04 × 10-1Fa |
Age at diagnosis (year) | 23.00 (20.00, 26.00) | 28.00 (24.00, 37.00) | 6.96 × 10 -3 W |
Age at presentation (year) | 22.50 (20.00, 25.50) | 25.00 (20.00, 32.00) | 1.71 × 10-1W |
Disease onset before 30 years, n (%) | 21 (91.30%) | 33 (66.00%) | 2.40 × 10 -2 C |
Serum parameters at presentation | |||
 Serum ferritin (ng/ml) | 3065.00 (2000.00, 4485.00) | 4018.50 (2500.00, 6008.50) | 1.23 × 10-1W |
 Transferrin saturation (%) | 95.00 (90.00, 100.00) | 96.00 (91.00, 100.00) | 5.62 × 10-1W |
Complications | |||
 Cardiomyopathy, n (%) | 7 (30.43%) | 21 (42.00%) | 3.45 × 10-1C |
 Skin hyperpigmentation, n (%) | 5 (21.74%) | 25 (50.00%) | 3.92 × 10 -2 F |
 Arthropathy, n (%) | 4 (17.39%) | 14 (28.00%) | 3.94 × 10-1F |
Endocrine abnormality | |||
 Hypogonadism, n (%) | 18 (78.26%) | 31 (62.00%) | 1.70 × 10-1C |
 Glucose intolerance, n (%) | 6 (26.09%) | 16 (32.00%) | 6.09 × 10-1C |
 Osteopathy, n (%) | 1 (4.35%) | 4 (8.00%) | 1.00 × 10-1F |
 Thyroid abnormality, n (%) | 0 (0.00%) | 3 (6.00%) | 5.47 × 10-1F |
Liver disease | |||
 Abnormal liver function test, n (%) | 8 (34.78%) | 19 (38.00%) | 7.91 × 10-1C |
 Liver iron deposition, n (%) | 15 (65.22%) | 35 (70.00%) | 6.83 × 10-1C |
 Liver fibrosis, n (%) | 12 (52.17%) | 20 (40.00%) | 3.30 × 10-1C |
 Liver cirrhosis, n (%) | 7 (30.43%) | 13 (26.00%)) | 6.93 × 10-1C |
 Liver biopsy, n (%) | 17 (73.91%) | 25 (50.00%) | 5.48 × 10-2C |
Therapy Phlebotomy/Chelating agent/Phlebotomy & Chelating agent/ND, n (%) | 6/0/2/15 (26.09/0.00/8.70/65.22) | 28/3/4/15 (56.00/6.00/8.00/30.00) | — |